| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Radiation Medicine [F. H. D.] and Pathology [D. M. G.], University of Kentucky College of Medicine; Nuclear Medicine Service of Veterans Administration Medical Center [E. E. K., G. S.]; and The Ephraim McDowell Community Cancer Network, Inc., Lexington, Kentucky 40536
External in vivo imaging of tumors with radioactively labeled antibodies to tumor-associated antigens requires processing to remove interfering nontarget radioactivity. Processing entails the use of simulated nontarget compounds labeled with a radionuclide physically different from that on the antibody and subtraction of the simulated nontarget activity from the nontargeted antibody. A 2-fold increase of the target to nontarget radioactivity is achieved that has made possible a greater than 70% tumor detection rate.
1 Presented at the UICC Workshop on Radioimmunodetection of Cancer, July 19 to 21, 1979, Lexington, Ky. Supported by National Cancer Institute Grant CA-25584 and by the Veterans Administration Central Office, Washington, D. C.
2 To whom requests for reprints should be addressed, at the University of Kentucky Medical Center, Room N-7, Lexington, Ky. 40536
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |